<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333916</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19.</ArticleTitle><Pagination><StartPage>1047</StartPage><MedlinePgn>1047</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09941-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Osteoporosis, a systemic skeletal disease, is characterized by a quantitative and qualitative, and progressive decrease in bone mass, which is related to inflammation. Since a cytokine storm is triggered in Coronavirus disease 2019 (COVID-19), this study aims to evaluate pro-inflammatory cytokines (TNF-α, IL-1β), Receptor activator of nuclear factor-κB ligand (RANKL)/serum osteoprotegerin (OPG) ratio, and their relationship in mild and severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was performed on 48 adult patients (18 mild, 18 severe COVID-19, and 12 healthy subjects as a control group). Serum OPG, RANKL, TNF-α, IL-1β, 25-OH vitamin D, and ALKp were measured by ELISA and colorimetric assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 patients had a significant increase in RANKL, and RANKL/OPG in mild and severe form (p &lt; 0.001) while OPG decreased significantly in severe form compared to healthy controls (p &lt; 0.05). Inflammatory cytokines (TNF-α and IL-1β) increased in both groups of patients whereas Alkaline phosphatase (ALKp) increased only in severe patients (p &lt; 0.001). Both groups had 25-OH vitamin D deficiency in comparison to healthy ones (p &lt; 0.001). Pearson's correlation coefficient was performed to determine the relationship between RANKL, OPG, ALKp, and 25-OH vitamin D with TNF-α and IL-1β in mild and severe COVID-19, which was statistically significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Serum RANKL/OPG ratio was elevated in COVID-19 individuals and is assumed to be a risk factor for BMD reduction and osteoporosis in these patients. Correlations between IL-1β, TNF-α, ALKp, 25-OH vitamin D, OPG, RANKL, and RANKL/OPG ratio offered the potential role of these proinflammatory markers in the mechanism of osteoporosis in COVID-19 patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kazemi-Sufi</LastName><ForeName>Siamak</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alipour</LastName><ForeName>Shahriar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Applied Cell Sciences, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabieepour</LastName><ForeName>Masome</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshan-Milani</LastName><ForeName>Shiva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurophysiology Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology and Kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naderi</LastName><ForeName>Roya</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8529-7306</Identifier><AffiliationInfo><Affiliation>Nephrology and Kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran. naderi.r@umsu.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. naderi.r@umsu.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053245">RANK Ligand</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505688">TNFSF11 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506030">TNFRSF11B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-16-2</RegistryNumber><NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>A288AR3C9H</RegistryNumber><NameOfSubstance UI="C104450">25-hydroxyvitamin D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053244" MajorTopicYN="Y">Osteoprotegerin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053245" MajorTopicYN="Y">RANK Ligand</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-1β</Keyword><Keyword MajorTopicYN="N">OPG</Keyword><Keyword MajorTopicYN="N">RANKL</Keyword><Keyword MajorTopicYN="N">TNF-α</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. The authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333916</ArticleId><ArticleId IdType="pmc">PMC11428542</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09941-6</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09941-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog. 2021;153:104799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biology. 2020;10:200160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536084</ArticleId><ArticleId IdType="pubmed">32961074</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London England). 2020;395:507–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapra L, Saini C, Garg B, Gupta R, Verma B, Mishra PK, Srivastava RK. Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics. Inflamm Research: Official J Eur Histamine Res Soc [et al]. 2022;71:1025–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330992</ArticleId><ArticleId IdType="pubmed">35900380</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvio G, Gianfelice C, Firmani F, Lunetti S, Balercia G, Giacchetti G. Bone metabolism in SARS-CoV-2 Disease: possible osteoimmunology and gender implications. Clin Rev Bone Miner Metab. 2020;18:51–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7459260</ArticleId><ArticleId IdType="pubmed">32904892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao H, Ge G, Li W, Liang X, Wang H, Li N, Sun H, Zhang W, Geng D. Dysimmunity and inflammatory storm: watch out for bone lesions in COVID-19 infection. Med Hypotheses. 2020;145:110332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536122</ArticleId><ArticleId IdType="pubmed">33039950</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzmann MN, Ofotokun I. Physiological and pathophysiological bone turnover - role of the immune system. Nat Reviews Endocrinol. 2016;12:518–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857945</ArticleId><ArticleId IdType="pubmed">27312863</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109:3839–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874582</ArticleId><ArticleId IdType="pubmed">17202317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad Khdhir K, Alipour S, Gholizadeh-Ghaleh Aziz S, Banihashemi SH. Investigating the relationship between the levels of IL18, RANKL gene expression, MicroRNA-146a and inflammatory factors with the severity of COVID-19. Iran J Allergy Asthma Immunol. 2023;22:82–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">37002633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Du J, Yu X, Xu J, Huang F, Li X, Zhang C, Li X, Chang J, Shang D. miRNA-200c-3p is crucial in acute respiratory distress syndrome. Cell Discovery. 2017;3:1–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485385</ArticleId><ArticleId IdType="pubmed">28690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, Illa I, Mantegazza R, Murai H, Utsugisawa K. (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105910</ArticleId><ArticleId IdType="pubmed">32247193</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K-B, Lee T-j, Hwang S-s. Disease severity classification and COVID-19 outcomes, Republic of Korea. Bull World Health Organ. 2021;99:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924894</ArticleId><ArticleId IdType="pubmed">33658735</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe R, Shiraki M, Saito M, Okazaki R, Inoue D. (2018) Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women. Osteoporos Int. 29:625–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29218382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B, Kim J, Jo YH, Kang SH, Lee YJ, Lee JH, Hwang JE, Park MJ, Lee S. Risk of Pneumonia after Vertebral Compression fracture in women with low bone density: a Population-based study. Spine. 2018;43:E830–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29283958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kottlors J, Große Hokamp N, Fervers P, Bremm J, Fichter F, Persigehl T, Safarov O, Maintz D, Tritt S, Abdullayev N. Early extrapulmonary prognostic features in chest computed tomography in COVID-19 pneumonia: bone mineral density is a relevant predictor for the clinical outcome - A multicenter feasibility study. Bone. 2021;144:115790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720732</ArticleId><ArticleId IdType="pubmed">33301962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahtabasi M, Kilicaslan N, Akin Y, Karaman E, Gezer M, Icen YK, Sahiner F. The Prognostic Value of vertebral bone density on chest CT in hospitalized COVID-19 patients. J Clin Densitometry: Official J Int Soc Clin Densitometry. 2021;24:506–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302819</ArticleId><ArticleId IdType="pubmed">34353732</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Formenti AM, Doga M, Pedone E, Rovere-Querini P, Giustina A. Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict Disease outcomes. J Clin Endocrinol Metab. 2021;106:e602–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797741</ArticleId><ArticleId IdType="pubmed">33159451</ArticleId></ArticleIdList></Reference><Reference><Citation>Awosanya OD, Dalloul CE, Blosser RJ, et al. Osteoclast-mediated bone loss observed in a COVID-19 mouse model. Bone. 2022;154:116227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486589</ArticleId><ArticleId IdType="pubmed">34607050</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao W, Lau HE, Xie H, Poon VK. (2022) SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. 13:2539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9085785</ArticleId><ArticleId IdType="pubmed">35534483</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar Ali S, Kang H, Olney R, Ramos-Platt L, Ryabets-Lienhard A, Cheung C, Georgia S, Pitukcheewanont P. Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation. USA. 2019;30:2283–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31392399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowska Z, Ziora K, Oświęcimska J, Marek B, Świętochowska E, Kajdaniuk D, Strzelczyk J, Cieślicka A, Wołkowska-Pokrywa K, Kos-Kudła B. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynologia Polska. 2015;66:313–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26323468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombak A, Boztepe B, Akbayir S, Dogru G, Sungur MA. Receptor activator of nuclear factor κ-Β Ligand/Osteoprotegerin Axis in adults with Hb S/β-Thalassemia and β-Thalassemia trait. Hemoglobin. 2020;44:334–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32873083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wędrychowicz A, Sztefko K, Majka M, Ratajczak MZ. The role of insulin-like growth factor 1, receptor activator for nuclear factor κB ligand - osteoprotegerin system, interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood. Endokrynologia Polska. 2013;64:248–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">24002950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R, Hammad A, El-Nahrery E, Hamdy N, Elhawary AK, Eid R. (2019) Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus. Lupus. 28:1233–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">31403902</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz-Junior CM, Santos A, Gonçalves MR, et al. Acute coronavirus infection triggers a TNF-dependent osteoporotic phenotype in mice. Life Sci. 2023;324:121750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10152759</ArticleId><ArticleId IdType="pubmed">37142087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerschan-Schindl K, Dovjak P, Butylina M, Rainer A, Mayr B, Röggla V, Haslacher H, Weber M, Jordakieva G, Pietschmann P. Moderate COVID-19 disease is Associated with reduced bone turnover. J bone Mineral Research: Official J Am Soc Bone Mineral Res. 2023;38:943–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">37126438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsourdi E, Hofbauer LC, Rauner M. (2022) The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 54:540–548.</Citation><ArticleIdList><ArticleId IdType="pubmed">35419776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. (2020) Cytokine Storm. 383:2255–2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes AL, Murai IH. (2022) Effect of a single high dose of vitamin D3 on cytokines, chemokines, and growth factor in patients with moderate to severe COVID-19. Randomized Controlled Trial. 115:790–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807215</ArticleId><ArticleId IdType="pubmed">35020796</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, Richards D, Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet (London England). 2020;395:1407–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158940</ArticleId><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SH, Minn D, Kim SW, Kim YK. (2021) Inflammatory markers and cytokines in moderate and critical cases of COVID-19. Clin Lab 67.</Citation><ArticleIdList><ArticleId IdType="pubmed">34542974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130:2620–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London England). 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;71:762–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N. (2020) Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 369:718–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (London England). 2003;361:1319–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J, Dejana E, Mantovani A. IL-1 stimulates IL-6 production in endothelial cells. J Immunol (Baltimore Md: 1950). 1989;142:549–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">2783442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D, Fahrleitner-Pammer A. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? Wien Med Wochenschr. 2010;160:452–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20714810</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatologica Portuguesa. 2011;36:209–18.</Citation><ArticleIdList><ArticleId IdType="pubmed">22113597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurado S, Garcia-Giralt N, Díez-Pérez A, et al. Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts. J Cell Biochem. 2010;110:304–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20225238</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275:4858–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671521</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamopoulos IE. Inflammation in bone physiology and pathology. Curr Opin Rheumatol. 2018;30:59–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963529</ArticleId><ArticleId IdType="pubmed">29016371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencel P, Delplace S, Pilet P, Leterme D, Miellot F, Sourice S, Caudrillier A, Hardouin P, Guicheux J, Magne D. Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest. 2011;91:1434–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencel P, Delplace S, Hardouin P, Magne D. TNF-α stimulates alkaline phosphatase and mineralization through PPARγ inhibition in human osteoblasts. Bone. 2011;48:242–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20832511</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba K, Takada J, Yamashita T. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab. 2004;22:594–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15490270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman K, Mustafa G, Ayub H, Ullah I, Alam MR, Khan MA. Expression analysis of tumour necrosis factor alpha (TNF-α) and alkaline phosphatase in occupational workers exposed to low dose of X-radiation: a case-control study. JPMA J Pakistan Med Association. 2020;70:1887–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">33341825</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J bone Mineral Research: Official J Am Soc Bone Mineral Res. 2000;15:1526–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">10934651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 11:76–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">10663362</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal AC, Behera AK, Mohapatra E, Sakale H, Shah SK, Kar B, Ojha MM, Nayak B, Garg AK. Correlation of vitamin D levels with markers of bone metabolism in COVID-19 patients. J Orthop Traumatol Rehabilitation. 2022;14:149–53.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>